BioMarin Pharmaceutical (BMRN) 10-K2003 FY Annual report

Filed: 27 Feb 04, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Avg

New words: Academy, adhere, adjunct, aim, ammonia, ample, Area, aware, Bay, Bayview, belief, catastrophic, category, channel, chemical, CIBC, clarify, climbed, cofactor, cognitive, collateralized, conference, convened, convenient, CTD, currency, decade, dedicated, defective, deteriorate, diet, dietary, disaster, disorder, distinction, dollar, doubtful, DSMB, ear, earthquake, eat, Eprova, extremely, faculty, fault, Francisco, GAAP, greatest, greatly, Guide, guiding, half, halt, halted, handling, history, hundred, hydroxylase, Ignacio, immunosuppressive, impossible, IND, Indenture, Individual, induced, Japanese, judgment, KGaA, LNAA, local, lost, lot, lung, lyase, Medicaid, Merck, minimal, moderate, municipal, Neuro, NIH, obsolete, outweigh, overcome, overstocking, PAH, PAL, Park, passed, persuasive, Phe, Phenoptin, pilot, poor, predetermined, proportionately, Quebec, recall, recommendation, recommended, reconciliation, recur, recurring, redemption, regular, renowned, scenario, settlement, shelf, sublet, Subordinated, substantive, Supply, Tetrahydrobiopertin, tetrahydrobiopterin, UBS, unblinded, unexpected, uninvested, unpaid, urquhart, vehicle, voluntarily, vulnerable, Wilmington, withdraw, worse

Removed: allergic, analytic, assumed, attracting, attractive, biologic, BLA, brokerage, buildup, burned, Carson, closed, collected, comparative, competing, compromised, cumulative, Denison, diagnostic, disability, economically, entity, exercised, facilitate, Founder, frequency, frequently, fulfill, fully, gather, glycosylation, grow, immaterial, implicated, inexpensive, infrastructure, internet, investigative, Jr, label, leverage, met, niche, outlined, phosphate, phosphorylation, physical, physician, proper, protocol, recently, removing, rentable, separate, short, showed, skeletal, source, Street, structural, substantially, suffering, tissue, TKTX, undergoing, uptake, validation

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

BMRN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.2

CONSENT OF INDEPENDENT ACCOUNTANTS

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (File Nos. 333-108972, 333-102066, 333-72866, 333-61322) and in the Registration Statements on Form S-8 (File Nos. 333-85368, 333-84787) of BioMarin Pharmaceutical Inc. of our report dated January 27, 2004 relating to the financial statements of BioMarin/Genzyme LLC, which is included an as exhibit to this Form 10-K.

/s/ PricewaterhouseCoopers LLP

Boston, Massachusetts

February 26, 2004